ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview Transcript
Good morning, and welcome to the ProQR Investor Call. Today's conference call is being recorded. At this time, I'd like to turn the call over to Sarah Kiely, Vice President of Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator. Good day, everyone. We appreciate you joining our call. I am Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR. Today, we were very pleased to announce, along with Lilly, the expansion of our partnership. This press release can be found on our website at www.proqr.com.
During today's call, we will provide an overview of the partnership expansion as well as review our broader strategy with our Axiomer RNA editing technology platform. We will also share some highlights from our recent Axiomer presentation at TIDES Europe.
On Slide 2, you'll find the agenda for the call and today's speakers. With me from the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |